Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace - Seite 2

Radiological imaging is the current standard in detecting tumor recurrence, but it suffers from low sensitivity and specificity, very often revealing relapsed cancer when it has progressed too far for effective treatment strategies. Fast non-invasive treatment response monitoring is critical for cancer patients to timely adjust drug doses or change drug choices.

Cyclomics has already developed an early detection technology called “CyclomicsSeq TP53”, an in vitro diagnostic (IVD) kit integrating an innovative sequencing methodology and state-of-the-art analysis software. Ninety percent of Head Neck Cancer (HNC) patients carry specific oncogenic DNA mutations in the gene TP53. There are 150,000 new cases every year in the EU and nearly 70,000 in the USA. The Cyclomics solution can be applied to other cancer types harboring TP53, such as small-cell lung cancer, squamous cell lung cancer, triple-negative breast cancer, and high-grade serous ovarian cancer, and can be expanded to almost all cancer types.

GEDiCube’s platform technology deploys next-generation AI running on NVIDIA's latest chips and stacks genetic and protein expression on top of DNA mutation for accuracy in cancer detection. GEDiCube is focused on developing advanced diagnostic and monitoring tests that use multi-omics, integrating data from each stage of genetic expression, including genomics, epigenomics, transcriptomics, proteomics, fragmentomics and metabolomics. As a member of the Nvidia Inception Program, the company will integrate medical imaging into its AI engine.

Upon closing, the combined companies will aim to accelerate entry into the cancer monitoring market and gain access to integrating whole genome data into GEDiCube’s AI/Machine Learning platform.

“We are very excited about this new opportunity,” said Alessio Marcozzi, PhD, co-founder of Cyclomics. “Our Omni-Omic technology was developed to help empower AI platforms and thereby transform non-invasive healthcare solutions to detect cancers and other diseases as early as possible. GEDiCube’s innovative deep learning algorithms have created robust multi-omics panels that perform remarkably well. Together, I believe we will change the field.” Coenraad van Kalken, MD, PhD, the CEO of GEDiCube, commented, “There is enormous power in applying AI to multiple omics data layers that can be detected from a vial of blood from every patient with cancer. I believe that integrating Cyclomics into GEDiCube will allow us to gain greater accuracy and widespread Omni-omic measurements through next-generation sequencing and enter the cancer monitoring market this year. I consider that to be a significant step towards bringing early detection of cancer to its inflection point.”